title: [Recommendation with serious adverse effects].
authors.forename: Wojciech
authors.initials: W
authors.lastname: Ruminski
authors.forename: Kristine
authors.initials: K
authors.lastname: Jensen
authors.forename: Tina M
authors.initials: TM
authors.lastname: Kringelbach
authors.forename: Ole
authors.initials: O
authors.lastname: Vang
authors.forename: Pierre N
authors.initials: PN
authors.lastname: Bouchelouche
authors.forename: Lars K
authors.initials: LK
authors.lastname: Munck
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D015179:Colorectal Neoplasms / Q000517:prevention & control; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D012307:Risk Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D001241:Aspirin